Gammagard Liquid Approved for Chronic Inflammatory Demyelina

Gammagard Liquid Approved for Chronic Inflammatory Demyelinating Polyneuropathy

The approval was based on data from the phase 3 ADVANCE-CIDP 2 study, which included 18 adults with CIDP who developed a relapse in the ADVANCE-CIDP 1 study after receiving treatment with HyQvia.

Related Keywords

, Drug Administration , Gammagard Liquid , Inflammatory Neuropathy Cause , Rasch Built Overall Disability Scale ,

© 2025 Vimarsana